search
EmCell
THE WORLDS LARGEST CLINICAL EXPERIENCE IN EMBRYONIC STEM CELL TRANSPLANTATION FOR
VARIOUS DISEASES AND CONDITIONS.

Home
About EmCell
IMPORTANT MESSAGE
EmCell Therapy
Our Experience
List of diseases
Oncology
Diabetes Mellitus
Nervous system
Aging Problems
Immune Deficiency
Endoscopic Treatment of Liver Diseases
News
Experience of Application of Embryonic Stem Cells in Amyotrophic Lateral Sclerosis
Embryonic Stem Cells in New-Onset Type 2 Diabetes Mellitus
Embryonic Stem Cells in Pernicious Decompensated Type 2 Diabetes Mellitus
Embryonic Stem Cell Transplantation in Multiple Sclerosis
Embryonic Cell Suspensions in Rheumatoid Arthritis
Investment Projects
Clinical Trials
Publications
Patents
Mail center
Congresses and Conferences

16 YEARS OF INTERNATIONAL CLINICAL EXPERIENCE IN TRANSPLANTATION OF HUMAN EMBRYONIC/FETAL STEM CELLS. REVIEW.

Clinical Trials

Dear Sirs,

Embryonic Tissues Center "EmCell" has unique own experience in clinical application of Embryonic Stem Cell Transplantation in different diseases, which most probably is the largest in the world now.

We would be glad to find reputable partners for Clinical Trials of Embryonic Stem Cell Therapy application in several diseases as soon as research in this field became acceptable in the USA.

We suggest for clinical trials the following diseases and conditions where we have definite positive experience:

- juvenile recently revealed insulin-dependent diabetes mellitus,
- agranulocytosis in oncology and hematology,
- AIDS and HIV infection,
- brain injury of different origins,
- Duchenne muscular dystrophy

We are open to discuss other applications for clinical trials as well.

We are ready to grant Embryonic Stem Cell Suspensions for such trials, provide scientific consulting and technical assistance to make Embryonic Stem Cell Therapy available in the USA.

Please, send your considerations and proposals to infocenter@emcell.com.


Professor Alexey Karpenko, MD.


Copyright © 1999-2008 EmCell.com     Create a WebsiteDeveloped by XTLabs, Inc.